AllenJMSurajbaliDQ NguyenD, et al.Impact of piperacillin-tazobactam dosing in septic shock patients using real-world evidence: an observational, retrospective cohort study. Ann Pharmacother. 2023;57(6):653-661.
2.
LodiseTPLomaestroBDrusanoGL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44:357-363.
3.
RobertsJALipmanJ. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840-859.
4.
ThabitAGrupperMNicolauDKutiJL. Simplifying piperacillin/tazobactam dosing: Pharmacodynamics of utilizing only 4.5 or 3.375 g doses for patients with normal and impaired renal function. J Pharm Pract. 2017;30:593-599.
5.
TammaPDHeilELJustoJAMathersAJSatlinMJBonomoRA. Infectious diseases society of America antimicrobial-resistant treatment guidance: gram-negative bacterial infections. Infectious diseases society of America, 2024. Version 4.0. https://www.idsociety.org/practice-guideline/amr-guidance/. Accessed 02 Aug 2024.
6.
GoldsteinSLMottesTSimpsonK, et al.A sustained quality improvement program reduces nephrotoxic medication-associated acute kidney injury. Kidney Int. 2016;90(1):212-221.
7.
RussellJALeeTSingerJDe BackerDAnnaneD. Days alive and free as an alternative to a mortality outcome in pivotal vasopressor and septic shock trials. J Crit Care. 2018;47:333-337. doi:10.1016/j.jcrc.2018.05.003
8.
MontiGBradicNMarzaroliM, et al.MERCY investigators. Continuous vs intermittent meropenem administration in critically ill patients with sepsis: the MERCY randomized clinical trial. JAMA. 2023;16:e2310598. doi:10.1001/jama.2023.10598
9.
EvansLRhodesAAlhazzaniW, et al.Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
